SE378110B - - Google Patents

Info

Publication number
SE378110B
SE378110B SE7206645A SE664572A SE378110B SE 378110 B SE378110 B SE 378110B SE 7206645 A SE7206645 A SE 7206645A SE 664572 A SE664572 A SE 664572A SE 378110 B SE378110 B SE 378110B
Authority
SE
Sweden
Application number
SE7206645A
Inventor
R L Brattsand
K G Claeson
Af Ekenstam B Thuresson
B A Thalen
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bofors Ab filed Critical Bofors Ab
Priority to SE7206645A priority Critical patent/SE378110B/xx
Priority to IL42154A priority patent/IL42154A/en
Priority to ZA732956A priority patent/ZA732956B/xx
Priority to AU55252/73A priority patent/AU478324B2/en
Priority to GB2219573A priority patent/GB1428416A/en
Priority to DE2323216A priority patent/DE2323216C3/de
Priority to CY1012A priority patent/CY1012A/xx
Priority to FI731543A priority patent/FI50711C/fi
Priority to US359913A priority patent/US3928326A/en
Priority to DK277073A priority patent/DK133249C/da
Priority to SU1918554A priority patent/SU468408A3/ru
Priority to FR7318126A priority patent/FR2185406B1/fr
Priority to NLAANVRAGE7306979,A priority patent/NL175917C/xx
Priority to BE131271A priority patent/BE799728A/xx
Priority to CA171,781A priority patent/CA1003402A/en
Priority to JP5623473A priority patent/JPS547794B2/ja
Publication of SE378110B publication Critical patent/SE378110B/xx
Priority to US05/629,390 priority patent/US3992534A/en
Priority to US05/629,493 priority patent/US3996359A/en
Priority to KE2969A priority patent/KE2969A/xx
Priority to HK490/79A priority patent/HK49079A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SE7206645A 1972-05-19 1972-05-19 SE378110B (enExample)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (enExample) 1972-05-19 1972-05-19
IL42154A IL42154A (en) 1972-05-19 1973-05-01 Process for the separation of stereoisomeric mixtures of 16a,17a-alkylidenedioxy-pregnane derivatives into their components and components obtained thereby
ZA732956A ZA732956B (en) 1972-05-19 1973-05-01 A process for the separation of stereoisomeric mixtures into their components and components obtained hereby
AU55252/73A AU478324B2 (en) 1972-05-19 1973-05-04 A process for the separation of stereoisomeric mixtures into their components and components obtained hereby
GB2219573A GB1428416A (en) 1972-05-19 1973-05-09 Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby
DE2323216A DE2323216C3 (de) 1972-05-19 1973-05-09 Verfahren zur Auftrennung von Stereoisomerengemischen von Pregna-1,4dien-11 -ol-33-dionen
CY1012A CY1012A (en) 1972-05-19 1973-05-09 Process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtainned thereby
FI731543A FI50711C (fi) 1972-05-19 1973-05-14 Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen.
US359913A US3928326A (en) 1972-05-19 1973-05-14 Process for the separation of stereoisomeric mixtures into their components and components obtained hereby
DK277073A DK133249C (da) 1972-05-19 1973-05-17 Fremgangsmade til opspaltning af stereoisomerblandinger af 16alfa,17alfa-alkylidendioxypregnan-11beta,21-diol-3,20-dioner
SU1918554A SU468408A3 (ru) 1972-05-19 1973-05-18 Способ разделени стереоизомерных смесей
FR7318126A FR2185406B1 (enExample) 1972-05-19 1973-05-18
NLAANVRAGE7306979,A NL175917C (nl) 1972-05-19 1973-05-18 Werkwijze voor het splitsen van isomere mengsels van steroiden, werkwijze voor het bereiden van een farmaceutisch preparaat en aldus verkregen gevormd farmaceutisch preparaat.
BE131271A BE799728A (fr) 1972-05-19 1973-05-18 Procede pour la separation de steredoisomeres de certains steroides
CA171,781A CA1003402A (en) 1972-05-19 1973-05-18 Process for the separation of steroisomeric mixtures into their components and components obtained hereby
JP5623473A JPS547794B2 (enExample) 1972-05-19 1973-05-19
US05/629,390 US3992534A (en) 1972-05-19 1975-11-06 Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
US05/629,493 US3996359A (en) 1972-05-19 1975-11-06 Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
KE2969A KE2969A (en) 1972-05-19 1979-06-20 A process for the separation of sterioisomeric mixtures of steroid acetalsinto, their components and components obtained thereby
HK490/79A HK49079A (en) 1972-05-19 1979-07-19 A process for the separation of stereoisomeric mixtures of steroid acetals into their components and components obtained thereby

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (enExample) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
SE378110B true SE378110B (enExample) 1975-08-18

Family

ID=20269238

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7206645A SE378110B (enExample) 1972-05-19 1972-05-19

Country Status (17)

Country Link
US (1) US3928326A (enExample)
JP (1) JPS547794B2 (enExample)
BE (1) BE799728A (enExample)
CA (1) CA1003402A (enExample)
CY (1) CY1012A (enExample)
DE (1) DE2323216C3 (enExample)
DK (1) DK133249C (enExample)
FI (1) FI50711C (enExample)
FR (1) FR2185406B1 (enExample)
GB (1) GB1428416A (enExample)
HK (1) HK49079A (enExample)
IL (1) IL42154A (enExample)
KE (1) KE2969A (enExample)
NL (1) NL175917C (enExample)
SE (1) SE378110B (enExample)
SU (1) SU468408A3 (enExample)
ZA (1) ZA732956B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404200A (en) * 1980-12-04 1983-09-13 Aktiebolaget Draco 4-Pregnene-derivatives, a process for their preparation, composition and method for the treatment of inflammatory conditions

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188581C (nl) * 1974-07-15 1992-08-03 Akzo Nv Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
ZA763131B (en) * 1975-05-27 1978-01-25 Syntex Inc Use of flunisolide to treat respiratory diseases
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
NZ259596A (en) * 1993-01-08 1997-04-24 Astra Ab Sugar-substituted glucocorticosteroid and use in medicaments specific to the colon or ileum
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP1737861A4 (en) 2004-04-09 2010-04-28 Merck Sharp & Dohme HEMMER OF ACT ACTIVITY
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US9408816B2 (en) 2006-12-26 2016-08-09 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
NZ579645A (en) 2007-03-14 2012-01-12 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
AU2010294598B2 (en) * 2009-09-11 2016-09-01 Chiesi Farmaceutici S.P.A. Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
JP2013518909A (ja) 2010-02-08 2013-05-23 キナゲン，インク． アロステリックキナーゼ阻害が関係する治療方法および組成物
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
JP6330118B2 (ja) 2011-09-13 2018-05-30 ファーマサイクリックス エルエルシー ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
BR112015003729A2 (pt) 2012-08-24 2018-06-05 Univ Texas composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
ES3046537T3 (en) 2016-11-08 2025-12-02 Regeneron Pharma Steroids and protein-conjugates thereof
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
SG11202006510XA (en) 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
CN118955710A (zh) 2018-05-09 2024-11-15 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12552826B2 (en) 2018-08-07 2026-02-17 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12595248B2 (en) 2019-12-17 2026-04-07 Merck Sharp & Dohme Llc PRMT5 inhibitors
BR112022012015A2 (pt) 2019-12-17 2022-08-30 Merck Sharp & Dohme Llc Inibidores de prmt5
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US20240116945A1 (en) 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
GEAP202516798A (en) 2022-12-14 2025-10-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404200A (en) * 1980-12-04 1983-09-13 Aktiebolaget Draco 4-Pregnene-derivatives, a process for their preparation, composition and method for the treatment of inflammatory conditions

Also Published As

Publication number Publication date
DE2323216B2 (de) 1977-11-03
DK133249C (da) 1976-09-13
FI50711B (enExample) 1976-03-01
KE2969A (en) 1979-07-20
NL175917C (nl) 1985-01-16
CY1012A (en) 1979-11-23
CA1003402A (en) 1977-01-11
HK49079A (en) 1979-07-27
FI50711C (fi) 1976-06-10
DE2323216A1 (de) 1973-11-29
NL7306979A (enExample) 1973-11-21
DE2323216C3 (de) 1978-06-22
IL42154A (en) 1976-12-31
FR2185406B1 (enExample) 1976-12-31
GB1428416A (en) 1976-03-17
JPS547794B2 (enExample) 1979-04-10
IL42154A0 (en) 1973-07-30
JPS4941379A (enExample) 1974-04-18
NL175917B (nl) 1984-08-16
SU468408A3 (ru) 1975-04-25
AU5525273A (en) 1974-11-07
DK133249B (da) 1976-04-12
BE799728A (fr) 1973-09-17
FR2185406A1 (enExample) 1974-01-04
ZA732956B (en) 1974-04-24
US3928326A (en) 1975-12-23

Similar Documents

Publication Publication Date Title
FR2185406B1 (enExample)
JPS4920858A (enExample)
JPS4997885A (enExample)
JPS4938505U (enExample)
JPS4879218A (enExample)
JPS48104157U (enExample)
CH562655A5 (enExample)
CH561697A5 (enExample)
CH572270A5 (enExample)
CH578010A5 (enExample)
CH571552A5 (enExample)
CH570557A5 (enExample)
CH569984A5 (enExample)
CH568774A5 (enExample)
CH578151A5 (enExample)
CH565657A5 (enExample)
CH563019A5 (enExample)
CH1043973A4 (enExample)
CH579543A5 (enExample)
CH562076A5 (enExample)
CH562045A5 (enExample)
CH561911A5 (enExample)
CH561814A (enExample)
CH574478A5 (enExample)
CH561308A5 (enExample)